Weight considerations in pharmacotherapy for type 2 diabetes

Journal of Obesity

Volumn 2011, Issue , 2011, Pages

  Cheng, Vicky ^a   Kashyap, Sangeeta R ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79952964075     PISSN: 20900708     EISSN: 20900716     Source Type: Journal    
DOI: 10.1155/2011/984245     Document Type: Review

References (64)

1. Narayan K. M. V., Boyle J. P., Thompson T. J., Gregg E. W., Williamson D. F., Effect of BMI on lifetime risk for diabetes in the U.S. Diabetes Care 2007 30 6 1562 1566 2-s2.0-34249896659 10.2337/dc06-2544 (Pubitemid 46871171)
2. Centers for Disease Control and Prevention (CDC), Prevalence of overweight and obesity among adults with diagnosed diabetes-United States, 1988-1994 and 1999-2002. Morbidity and Mortality Weekly Report 2004 53 45 1066 1068
3. Goldstein B. J., Insulin resistance as the core defect in type 2 diabetes mellitus. American Journal of Cardiology 2002 90 5 3G 10G 2-s2.0-0037026739 (Pubitemid 35266675)
4. DeFronzo R. A., Pathogenesis of type 2 diabetes mellitus. Medical Clinics of North America 2004 88 4 787 835 2-s2.0-4143151942 10.1016/j.mcna.2004.04.013 (Pubitemid 39090340)
5. Knowler W. C., Barrett-Connor E., Fowler S. E., Hamman R. F., Lachin J. M., Walker E. A., Nathan D. M., Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine 2002 346 6 393 403 2-s2.0-0037034257 10.1056/NEJMoa012512 (Pubitemid 34437694)
6. Turner R., Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998 352 9131 837 853 2-s2.0-0032511580 10.1016/S0140-6736(98)07019-6 (Pubitemid 28416718)
7. Friedewald W. T., Buse J. B., Bigger J. T., Byington R. P., Cushman W. C., Gerstein H. C., Ginsberg H. N., Goff Jr. D. C., Grimm Jr. R. H., Ismail-Beigi F., Probstfield J. L., Simons-Morton D.G., Effects of intensive glucose lowering in type 2 diabetes. New England Journal of Medicine 2008 358 24 2545 2559 2-s2.0-33745265251 10.1056/NEJMoa0802743 (Pubitemid 351831356)
8. Mäkimattila S., Nikkilä K., Yki-Järvinen H., Causes of weight gain during insulin therapy with and without metformin in patients with Type II diabetes mellitus. Diabetologia 1999 42 4 406 412 2-s2.0-0344609217 10.1007/s001250051172 (Pubitemid 29148398)
9. Nathan D. M., Buse J. B., Davidson M. B., Ferrannini E., Holman R. R., Sherwin R., Zinman B., Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the american diabetes association and the european association for the study of diabetes. Clinical Diabetes 2009 27 1 4 16 2-s2.0-59349100028 10.2337/diaclin.27.1.4
10. Rosenstock J., Samols E., Muchmore D. B., Schneider J., Glimepiride, a new once-daily sulfonylurea: a double-blind placebo-controlled study of NIDDM patients. Diabetes Care 1996 19 11 1194 1199 2-s2.0-0029904041
11. Simonson D. C., Kourides I. A., Feinglos M., Shamoon H., Fischette C. T., Efficacy, safety, and dose-response characteristics of glipizide gastrointestinal therapeutic system on glycemic control and insulin secretion in NIDDM. Results of two multicenter, randomized, placebo-controlled clinical trials. Diabetes Care 1997 20 4 597 606 2-s2.0-0020318942 (Pubitemid 27143421)
12. Garber A. J., Donovan D. S. Jr., Dandona P., Bruce S., Park J.-S., Efficacy of glyburide/metformin tablets compared with initial monotherapy in type 2 diabetes. Journal of Clinical Endocrinology and Metabolism 2003 88 8 3598 3604 2-s2.0-0043132411 10.1210/jc.2002-021225 (Pubitemid 37034501)
13. Hanley A. J., anthony.hanley@utoronto.ca Zinman B., Sheridan P., Yusuf S., Gerstein H. C., Effect of rosiglitazone and ramipril on β -cell function in people with impaired glucose tolerance or impaired fasting glucose. Diabetes Care 2010 33 3 608 613 2-s2.0-0035042679 10.2337/dc09-1579
14. Xiang A. H., Peters R. K., Kjos S. L., Marroquin A., Goico J., Ochoa C., Kawakubo M., Buchanan T. A., Effect of pioglitazone on pancreatic β -cell function and diabetes risk in Hispanic women with prior gestational diabetes. Diabetes 2006 55 2 517 522 2-s2.0-33644762010 10.2337/diabetes.55.02.06.db05- 1066 (Pubitemid 43343284)
15. Dormandy J. A., Charbonnel B., Eckland D. J., Erdmann E., Massi-Benedetti M., Moules I. K., Skene A. M., Tan M. H., Lefèbvre P. J., Murray G. D., Standl E., Wilcox R. G., Wilhelmsen L., Betteridge J., Birkeland K., Golay A., Heine R. J., Korányi L., Laakso M., Mokáň M., Norkus A., Pirags V., Podar T., Scheen A., Scherbaum W., Schernthaner G., Schmitz O., Škrha J., Smith U., Tatoň J., Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial in macroVascular Events): a randomised controlled trial. Lancet 2005 366 9493 1279 1289 2-s2.0-26244453309 10.1016/S0140-6736(05)67528-9 (Pubitemid 41416583)
16. Kahn S. E., Haffner S. M., Heise M. A., Herman W. H., Holman R. R., Jones N. P., Kravitz B. G., Lachin J. M., O'Neill M. C., Zinman B., Viberti G., Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. New England Journal of Medicine 2006 355 23 2427 2443 2-s2.0-33845405222 10.1056/NEJMoa066224 (Pubitemid 44903747)
17. Miyazaki Y., Mahankali A., Matsuda M., Mahankali S., Hardies J., Cusi K., Mandarino L. J., DeFronzo R. A., Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. Journal of Clinical Endocrinology and Metabolism 2002 87 6 2784 2791 2-s2.0-0036072223 10.1210/jc.87.6.2784 (Pubitemid 34655345)
18. Frye R. L., August P., Brooks M. M., Hardison R. M., Kelsey S. F., MacGregor J. M., Orchard T. J., Chaitman B. R., Genuth S. M., Goldberg S. H., Hlatky M. A., Jones T. L. Z., Molitch M. E., Nesto R. W., Sako E. Y., Sobel B. E., A randomized trial of therapies for type 2 diabetes and coronary artery disease. New England Journal of Medicine 2009 360 24 2503 2515 2-s2.0-67149142042 10.1056/NEJMoa0805796
19. DeFronzo R. A., Triplitt C., Qu Y., Lewis M. S., Maggs D., Glass L. C., Effects of exenatide plus rosiglitazone on beta-cell function and insulin sensitivity in subjects with type 2 diabetes on metformin. Diabetes care 2010 33 5 951 957
20. Weng J., Li Y., Xu W., Shi L., Zhang Q., Zhu D., Hu Y., Zhou Z., Yan X., Tian H., Ran X., Luo Z., Xian J., Yan L., Li F., Zeng L., Chen Y., Yang L., Yan S., Liu J., Li M., Fu Z., Cheng H., Effect of intensive insulin therapy on β -cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. The Lancet 2008 371 9626 1753 1760 2-s2.0-43849105857 10.1016/S0140-6736(08)60762-X (Pubitemid 351697950)
21. Xu W., Li Y.-B., Deng W.-P., Hao Y.-T., Weng J.-P., Remission of hyperglycemia following intensive insulin therapy in newly diagnosed type 2 diabetic patients: a long-term follow-up study. Chinese Medical Journal 2009 122 21 2554 2559 2-s2.0-0027480065 10.3760/cma.j.issn.0366-6999.2009.21.006
22. Barnett A., Allsworth J., Jameson K., Mann R., A review of the effects of antihyperglycaemic agents on body weight: the potential of incretin targeted therapies. Current Medical Research and Opinion 2007 23 7 1493 1507 2-s2.0-34547161425 10.1185/030079907X199691 (Pubitemid 47122158)
23. Rosenstock J., Davies M., Home P. D., Larsen J., Koenen C., Schernthaner G., A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia 2008 51 3 408 416 2-s2.0-39049105019 10.1007/s00125-007-0911-x
24. Holman R. R., Thorne K. I., Farmer A. J., Davies M. J., Keenan J. F., Paul S., Levy J. C., Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. New England Journal of Medicine 2007 357 17 1716 1730 2-s2.0-35548947584 10.1056/NEJMoa075392 (Pubitemid 350005153)
25. DeFronzo R. A., Goodman A. M., Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. the multicenter metformin study group. The New England Journal of Medicine 1995 333 9 541 549
26. Garber A., Klein E., Bruce S., Sankoh S., Mohideen P., Metformin-glibenclamide versus metformin plus rosiglitazone in patients with type 2 diabetes inadequately controlled on metformin monotherapy. Diabetes, Obesity and Metabolism 2006 8 2 156 163 2-s2.0-33645996998 10.1111/j.1463-1326. 2005.00570.x
27. Vella A., Lee J. S., Camilleri M., Szarka L. A., Burton D. D., Zinsmeister A. R., Rizza R. A., Klein P. D., Effects of pramlintide, an amylin analogue, on gastric emptying in type 1 and 2 diabetes mellitus. Neurogastroenterology and Motility 2002 14 2 123 131 2-s2.0-0036248752 10.1046/j.1365-2982.2002.00311.x (Pubitemid 34451212)
28. Fineman M., Weyer C., Maggs D. G., Strobel S., Kolterman O. G., The human amylin analog, pramlintide, reduces postprandial hyperglucagonemia in patients with type 2 diabetes mellitus. Hormone and Metabolic Research 2002 34 9 504 508 2-s2.0-0036751254 10.1055/s-2002-34790 (Pubitemid 35192237)
29. Chapman I., Parker B., Doran S., Feinle-Bisset C., Wishart J., Strobel S., Wang Y., Burns C., Lush C., Weyer C., Horowitz M., Effect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes. Diabetologia 2005 48 5 838 848 2-s2.0-18844392661 10.1007/s00125-005-1732-4 (Pubitemid 40767975)
30. Hollander P. A., Levy P., Fineman M. S., Maggs D. G., Shen L. Z., Strobel S. A., Weyer C., Kolterman O. G., Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care 2003 26 3 784 790 2-s2.0-0042167233 10.2337/diacare.26.3.784 (Pubitemid 36929344)
31. Riddle M., Pencek R., Charenkavanich S., Lutz K., Wilhelm K., Porter L., Randomized comparison of pramlintide or mealtime insulin added to basal insulin treatment for patients with type 2 diabetes. Diabetes Care 2009 32 9 1577 1582 2-s2.0-69549130787 10.2337/dc09-0395
32. Smith S. R., Aronne L. J., Burns C. M., Kesty N. C., Halseth A. E., Weyer C., Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity. Diabetes Care 2008 31 9 1816 1823 2-s2.0-56149124659 10.2337/dc08-0029
33. Vilsbøll T., Krarup T., Deacon C. F., Madsbad S., Holst J. J., Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 2001 50 3 609 613 2-s2.0-0001095690 (Pubitemid 32195226)
34. Nauck M. A., Homberger E., Siegel E. G., Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. Journal of Clinical Endocrinology and Metabolism 1986 63 2 492 498 2-s2.0-0022461548 (Pubitemid 16035703)
35. Drucker D. J., Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care 2003 26 10 2929 2940 2-s2.0-0141446228 10.2337/diacare.26.10.2929 (Pubitemid 37205571)
36. Meier J. J., Gallwitz B., Salmen S., Goetze O., Holst J. J., Schmidt W. E., Nauck M. A., Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes. Journal of Clinical Endocrinology and Metabolism 2003 88 6 2719 2725 2-s2.0-0037667613 (Pubitemid 36733545)
37. Flint A., Raben A., Ersbøll A. K., Holst J. J., Astrup A., The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity. International Journal of Obesity 2001 25 6 781 792 2-s2.0-0032005005 (Pubitemid 32601369)
38. Farilla L., Hongxiang H., Bertolotto C., Kang E., Bulotta A., Mario U. D. I., Perfetti R., Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in zucker diabetic rats. Endocrinology 2002 143 11 4397 4408 2-s2.0-0036828227 10.1210/en.2002-220405 (Pubitemid 35239574)
39. DeFronzo R. A., Ratner R. E., Han J., Kim D. D., Fineman M. S., Baron A. D., Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005 28 5 1092 1100 2-s2.0-18144401971 10.2337/diacare.28.5.1092 (Pubitemid 40616618)
40. Ratner R. E., Maggs D., Nielsen L. L., Stonehouse A. H., Poon T., Zhang B., Bicsak T. A., Brodows R. G., Kim D. D., Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus. Diabetes, Obesity and Metabolism 2006 8 4 419 428 2-s2.0-33748471110 10.1111/j.1463-1326.2006.00589.x (Pubitemid 44349234)
41. Klonoff D. C., Buse J. B., Nielsen L. L., Guan X., Bowlus C. L., Holcombe J. H., Wintle M. E., Maggs D. G., Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Current Medical Research and Opinion 2008 24 1 275 286 2-s2.0-38549162147 10.1185/030079907X253870 (Pubitemid 351160260)
42. Bunck M. C., Diamant M., Cornér A., Eliasson B., Malloy J. L., Shaginian R. M., Deng W., Kendall D. M., Taskinen M.-R., Smith U., Yki-Järvinen H., Heine R. J., One-year treatment with exenatide improves β -cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. Diabetes Care 2009 32 5 762 768 2-s2.0-65949122087 10.2337/dc08-1797
43. Rosenstock J., Klaff L. J., Schwartz S., Northrup J., Holcombe J. H., Wilhelm K., Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without prediabetes. Diabetes Care 2010 33 6 1173 1175
44. Jendle J., Nauck M. A., Matthews D. R., Frid A., Hermansen K., Düring M., Zdravkovic M., Strauss B. J., Garber A. J., Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes, Obesity and Metabolism 2009 11 12 1163 1172 2-s2.0-70450190143 10.1111/j.1463-1326.2009.01158.x
45. Garber A., Henry R., Ratner R., Garcia-Hernandez P. A., Rodriguez-Pattzi H., Olvera-Alvarez I., Hale P. M., Zdravkovic M., Bode B., Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. The Lancet 2009 373 9662 473 481 2-s2.0-59449101432 10.1016/S0140-6736(08)61246-5
46. Zinman B., Gerich J., Buse J. B., Lewin A., Schwartz S., Raskin P., Hale P. M., Zdravkovic M., Blonde L., Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care 2009 32 7 1224 1230 2-s2.0-67650066860 10.2337/dc08-2124
47. Russell-Jones D., Vaag A., Schmitz O., Sethi B. K., Lalic N., Antic S., Zdravkovic M., Ravn G. M., Simó R., Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia 2009 52 10 2046 2055 2-s2.0-69949117621 10.1007/s00125-009-1472-y
48. Buse J. B., Rosenstock J., Sesti G., Schmidt W. E., Montanya E., Brett J. H., Zychma M., Blonde L., Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). The Lancet 2009 374 9683 39 47 2-s2.0-67649666737 10.1016/S0140-6736(09)60659-0
49. Astrup A., Rössner S., Van Gaal L., Rissanen A., Niskanen L., Al Hakim M., Madsen J., Rasmussen M. F., Lean M. E., Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. The Lancet 2009 374 9701 1606 1616 2-s2.0-70350619609 10.1016/S0140-6736(09)61375-1
50. Aschner P., Kipnes M. S., Lunceford J. K., Sanchez M., Mickel C., Williams-Herman D. E., Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006 29 12 2632 2637 2-s2.0-33845472504 10.2337/dc06-0703 (Pubitemid 44912190)
51. Goldstein B. J., Feinglos M. N., Lunceford J. K., Johnson J., De W.-H., Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care 2008 31 8 1979 1987 2-s2.0-64349100174
52. DeFronzo R. A., Hissa M. N., Garber A. J., Gross J. L., Duan R. Y., Ravichandran S., Chen R. S., The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes Care 2009 32 9 1649 1655 2-s2.0-69549135336 10.2337/dc08-1984
53. Guerciolini R., Mode of action of orlistat. International Journal of Obesity 1997 21 supplement 3 S12 S23 2-s2.0-0029973880 (Pubitemid 27271984)
54. Torgerson J. S., Hauptman J., Boldrin M. N., Sjöström L., XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004 27 1 155 161 2-s2.0-1042303480 10.2337/diacare.27.1.155 (Pubitemid 38196725)
55. Jacob S., Rabbia M., Meier M. K., Hauptman J., Orlistat 120 mg improves glycaemic control in type 2 diabetic patients with or without concurrent weight loss. Diabetes, Obesity and Metabolism 2009 11 4 361 371 2-s2.0-61549134855 10.1111/j.1463-1326.2008.00970.x
56. Berne C., A randomized study of orlistat in combination with a weight management programme in obese patients with Type 2 diabetes treated with metformin. Diabetic Medicine 2005 22 5 612 618 2-s2.0-0035169826 10.1111/j.1464-5491.2004.01474.x (Pubitemid 40593138)
57. Miles J. M., Leiter L., Hollander P., Wadden T., Anderson J. W., Doyle M., Foreyt J., Aronne L., Klein S., Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin. Diabetes Care 2002 25 7 1123 1128 2-s2.0-0036634125 10.2337/diacare.25.7.1123 (Pubitemid 41071161)
58. Kelley D. E., Bray G. A., Pi-Sunyer F. X., Klein S., Hill J., Miles J., Hollander P., Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care 2002 25 6 1033 1041 2-s2.0-0036598137 10.2337/diacare.25.6. 1033 (Pubitemid 41110490)
59. Barkeling B., britta.barkeling@medhs.ki.se Elfhag K., Rooth P., Rössner S., Short-term effects of sibutramine (Reductil) on appetite and eating behaviour and the long-term therapeutic outcome. International Journal of Obesity 2003 27 6 693 700 2-s2.0-0034710218 10.1038/sj.ijo.0802298 (Pubitemid 36712953)
60. Hauner H., Meier M., Wendland G., Kurscheid T., Lauterbach K., Weight reduction by sibutramine in obese subjects in primary care medicine: the S.A.T. study. Experimental and Clinical Endocrinology and Diabetes 2004 112 4 201 207 2-s2.0-2442503515 10.1055/s-2004-817934 (Pubitemid 38639291)
61. Aronne L. J., Halseth A. E., Burns C. M., Miller S., Shen L. Z., Enhanced weight loss following coadministration of pramlintide with sibutramine or phentermine in a multicenter trial. Obesity 2010 18 9 1739 1746
62. McNulty S. J., Ur E., Williams G., garethw@liverpool.ac.uk A randomized trial of sibutramine in the management of obese type 2 diabetic patients treated with metformin. Diabetes Care 2003 26 1 125 131 2-s2.0-0026606120 10.2337/diacare.26.1.125 (Pubitemid 36929004)
63. Gokcel A., Karakose H., Ertorer E. M., Tanaci N., Tutuncu N. B., Guvener N., Effects of sibutramine in obese female subjects with type 2 diabetes and poor blood glucose control. Diabetes Care 2001 24 11 1957 1960 2-s2.0-0035512619 (Pubitemid 33716508)
64. T. James W. Philip, Caterson Ian D., Coutinho Walmir, Finer Nick, Van Gaal Luc F., Maggioni Aldo P., Torp-Pedersen Christian, Sharma Arya M., Shepherd Gillian M., Rode Richard A., Renz Cheryl L., Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects. The New England Journal of Medicine 2010 363 10 905 917